Skip to main content

Table 3 Antimicrotubule trials: PSA and tumor response.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial Treatment arms PSA response* Tumor response
   N Response rate % Statistical comparison N Objective response rate % Statistical comparison
Tannock, 2004 [64] docetaxel q 3 wks prednisone 291 45 p < 0.001 141 12 p = 0.1
  docetaxel q wk prednisone 291 48 p < 0.001 134 8 p = 0.6
  Mitoxantrone prednisone 300 32 NA 137 7 NA
Petrylak, 2004 [63] Docetaxel EMP 309 50 p < 0.001 103 17 p < 0.30
  Mitoxantrone prednisone 303 27   93 11  
Abratt, 2004 [62] Vinorelbine hydrocortisone ± AGM 206 30.1 p < 0.01 68 5.9(PR) NR
  hydrocortisone ± AGM 208 19.2   74 0  
Berry, 2001 [84] Paclitaxel EMP 166 48 p < 0.01 NR
  Paclitaxel   25     
Hudes, 1999 [61] vinblastine EMP 87 25.2 p < 0.0001 30 20 (PR) p = 0.13
  Vinblastine 94 3.2   33 6 (PR)  
Iversen, 1997 [65] EMP 43 37.2 p = 0.001 NR
  Placebo 51 2.0     
Johansson, 1991 [66] EMP NR    NR
  MPA       
De Kernion, 1988 [67] EMP NR    102 0 p = NS
  Flutamide     101 1.0 (PR)  
Murphy, 1979 [68] EMP prednimustine NR    54 1.9 (PR) p = NS
  prednimustine     62 0  
  1. *PSA response was defined as = 50 decrease in PSA compared with baseline.
  2. Abbreviations: AGM – aminoglutethimide; EMP – estramustine phosphate; MPA – medroxyprogesterone acetate; N – number; NA – not applicable; NR – not reported; NS – non-significant; PR – partial response; PSA – prostate-specific-antigen; q – every; wk(s) – week(s).